1 Lennon, P., M. Crotty, and J.E. Fenton. Infectious mononucleosis. Bmj, 2015. 350: p. h1825.
2 Ebell M.H. Epstein-Barr virus infectious mononucleosis. Am Fam Physician. 2004;70(7):1279–87.
3 Womack, J. and M. Jimenez. Common questions about infectious mononucleosis. Am Fam Physician. 2015;91(6):372–6.
4 Dunmire, S.K., K.A. Hogquist, and H.H. Balfour. Infectious Mononucleosis. Curr Top Microbiol Immunol. 2015;390(Pt 1):211–40.
5 Balfour, H.H., Jr., S.K. Dunmire, and K.A. Hogquist. Infectious mononucleosis. Clin Transl Immunology. 2015;4(2):e33.
6 Fugl, A. and C.L. Andersen. Epstein-Barr virus and its association with disease-a review of relevance to general practice. BMC family practice, 2019;20(1):62.
7 Tattevin, P., Crémieux, A. C., Descamps, D., & Carbon, C. Transfusion-related infectious mononucleosis. Scandinavian journal of infectious diseases. 2002;34(10):777–8.
8 Kern, W., D. Wagner, and H. Hirsch. Infektionen nach Organtransplantation. Der Internist. 2005;46(6):630–42.
9 Odumade, O.A., K.A. Hogquist, and H.H. Balfour, Jr., Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin Microbiol Rev. 2011;24(1):193–209.
10 Fleisher, G.R., et al. Intrafamilial transmission of Epstein-Barr virus infections. J Pediatr. 1981;98(1):16–9.
11 Sumaya, C.V., et al. Seroepidemiologic study of Epstein-Barr virus infections in a rural community. The Journal of Infectious Diseases. 1975;131(4):403–8.
12 Luzuriaga, K. and J.L. Sullivan. Infectious mononucleosis. N Engl J Med. 2010;362(21):1993–2000.
13 Balfour, H.H., Jr., et al. Age-specific prevalence of Epstein-Barr virus infection among individuals aged 6-19 years in the United States and factors affecting its acquisition. J Infect Dis. 2013;208(8):1286–93.
14 Rickinson, A.B. and C.P. Fox. Epstein-Barr virus and infectious mononucleosis: what students can teach us. J Infect Dis. 2013;207(1):6–8.
15 Auwaerter P.G. Infectious Mononucleosis in Middle Age. JAMA. 1999;281(5):454–9.
16 Nye, F.J. Social class and infectious mononucleosis. J Hyg (Lond), 1973;71(1):145–9.
17 Hickey, S.M. and V.C. Strasburger. What every pediatrician should know about infectious mononucleosis in adolescents. Pediatric Clinics of North America. 1997;44(6):1541–56.
18 Putukian, M., et al. Mononucleosis and athletic participation: an evidence-based subject review. Clin J Sport Med. 2008:18(4):309–15.
19 Balfour, H.H., Jr., et al. A prospective clinical study of Epstein-Barr virus and host interactions during acute infectious mononucleosis. J Infect Dis. 2005;192(9):1505–12.
20 Crawford, D.H., et al. Sexual history and Epstein-Barr virus infection. J Infect Dis. 2002;186(6):731–6.
21 Woodman, C.B.J., et al. Role of Sexual Behavior in the Acquisition of Asymptomatic Epstein-Barr Virus Infection. The Pediatric Infectious Disease Journal. 2005;24(6):498–502.
22 Crawford, D.H., et al. A cohort study among university students: identification of risk factors for Epstein-Barr virus seroconversion and infectious mononucleosis. Clinical infectious diseases. 2006;43(3):276–82.
23 Balfour, H.H., Jr., et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein-Barr virus infection in university students. J Infect Dis. 2013;207(1):80–8.
24 Fafi-Kremer, S. et al. Long-term shedding of infectious epstein-barr virus after infectious mononucleosis. J Infect Dis. 2005;191(6):985–9.
25 Landau, Z. et al. Presence of infective Epstein-Barr virus in the urine of patients with infectious mononucleosis. J Med Virol. 1994;44(3):229–33.
26 Avgil, M. and A. Ornoy. Herpes simplex virus and Epstein-Barr virus infections in pregnancy: consequences of neonatal or intrauterine infection. Reproductive Toxicology, 2006;21(4):436–45.
27 Fleisher, G. and R. Bolognese. Persistent Epstein-Barr virus infection and pregnancy. Journal of Infectious Diseases. 1983;147(6):982–6.
28 Kusuhara, K., et al. Breast milk is not a significant source for early Epstein-Barr virus or human herpesvirus 6 infection in infants: a seroepidemiologic study in 2 endemic areas of human T-cell lymphotropic virus type I in Japan. Microbiol Immunol. 1997;41(4):309–12.
29 Grose, C. The many faces of infectious mononucleosis: the spectrum of Epstein-Barr virus infection in children. Pediatr Rev. 1985;7(2):35–44.
30 Cohen, J.I. Benign and malignant Epstein-Barr virus-associated B-cell lymphoproliferative diseases. Semin Hemato., 2003;40(2):116–23.
31 Grotto, I. et al. Clinical and laboratory presentation of EBV positive infectious mononucleosis in young adults. Epidemiology and Infection. 2003;131(1):683–9.
32 Cohen, J.I. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481–92.
33 Rea, T.D., et al. Prospective study of the natural history of infectious mononucleosis caused by Epstein-Barr virus. J Am Board Fam Pract. 2001;14(4):234–42.
34 Taga, K., H. Taga, and G. Tosato. Diagnosis of atypical cases of infectious mononucleosis. Clin Infect Dis. 2001;33(1):83–8.
35 Schmader, K.E., C.M. van der Horst, and M.E. Klotman. Epstein-Barr virus and the elderly host. Reviews of infectious diseases. 1989;11(1):64–73.
36 Finkel, M., G.W. Parker, and H.A. Fanselau. The hepatitis of infectious mononucleosis: experience with 235 cases. Military medicine. 1964;129:533–8.
37 Kofteridis, D.P., et al. Epstein Barr virus hepatitis. European journal of internal medicine. 2011;22(1):73–6.
38 Hurt, C. and D. Tammaro. Diagnostic evaluation of mononucleosis-like illnesses. Am J Med. 2007;120(10): p. 911 e1-8.
39 White, N.J. and B.E. Juel-Jensen. Infectious mononucleosis hepatitis. Semin Liver Dis. 1984;4(4):301–6.
40 Del, C.M. and D. Pincus. Incidence patterns of respiratory illness in Queensland estimated from sentinel general practice. Australian family physician. 1995;24(4):625–9, 632.
41 Aronson, M.D., et al. Heterophil antibody in adults with sore throat: frequency and clinical presentation. Ann Intern Med. 1982;96(4):505–8.
42 Genootschap, N.H. NHG-Standaard Acute keelpijn (derde herziening) [Internet]. 2015; Available from: https://www.nhg.org/standaarden/volledig/nhg-standaard-acute-keelpijn.
43 Zwart, S., et al. Penicillin for acute sore throat in children: randomised, double blind trial. BMJ. 2003;327(7427):1324.
44 C.F. Dagnelie, S.Z., F.A. Balder, A.C.M. Romeijnders, R.M.M. Geijer. NHG Standard “acute sore throat [Internet]. 1999; Available from: https://www.nhg.org/standaarden/volledig/nhg-standaard-acute-keelpijn.
45 Wessels, M.R. Clinical practice. Streptococcal pharyngitis. N Engl J Med. 2011;364(7):648–55.
46 Linde, A, Diagnosis of Epstein-Barr virus-related diseases. Scand J Infect Dis Suppl. 1996;100:83–8.
47 Robertson, P., et al. Measurement of EBV – IgG anti – VCA avidity aids the early and reliable diagnosis of primary EBV infection. Journal of medical virology. 2003;70(4):617–23.
48 Bell, A.T., B. Fortune, and R. Sheeler. Clinical inquiries. What test is the best for diagnosing infectious mononucleosis? J Fam Pract. 2006;55(9):799–802.
49 Elgh, F. and M. Linderholm. Evaluation of six commercially available kits using purified heterophile antigen for the rapid diagnosis of infectious mononucleosis compared with Epstein-Barr virus-specific serology. Clin Diagn Virol. 1996;7(1):17–21.
50 Ebell, M.H., et al. Does This Patient Have Infectious Mononucleosis?: The Rational Clinical Examination Systematic Review. JAMA. 2016;315(14):1502–9.
51 Nystad, T.W. and H. Myrmel. Prevalence of primary versus reactivated Epstein-Barr virus infection in patients with VCA IgG-, VCA IgM- and EBNA-1-antibodies and suspected infectious mononucleosis. J Clin Virol. 2007;38(4):292–7.
52 Vetter, V., L. Kreutzer, and G. Bauer. Differentiation of primary from secondary anti-EBNA-1-negative cases by determination of avidity of VCA-IgG. Clin Diagn Virol. 1994;2(1):29–39.
53 De Paschale, M., et al. Seroepidemiology of EBV and interpretation of the “isolated VCA IgG” pattern. Journal of Medical Virology. 2009;81(2):325–31.
54 De Paschale, M. and P. Clerici. Serological diagnosis of Epstein-Barr virus infection: problems and solutions. World journal of virology. 2012;1(1):31.
55 Kimura, H. and J.I. Cohen. Chronic Active Epstein-Barr Virus Disease. Frontiers in immunology. 2017;8:1867.
56 Karrer, U. and D. Nadal. Epstein-Barr-Virus und infektiöse Mononukleose. Swiss medical forum. 2014;14:226–32.
57 Kimura, H., et al. Measuring Epstein-Barr virus (EBV) load: the significance and application for each EBV-associated disease. Reviews in Medical Virology.2008;18(5):305–19.
58 Martelius, T., et al. Clinical characteristics, outcome and the role of viral load in nontransplant patients with Epstein-Barr viraemia. Clin Microbiol Infect. 2010;16(6):657–62.
59 Tarr, P., et al. HIV-Infektion. Swiss Medical Forum. 2015;15(2021):479–85.
60 Bundesamt für Gesundheit, Übertragbare Krankheiten: Richtlinie des BAG zum HIV-Test auf Initiative des Arztes/der Ärztin. Available from: Der HIV-Test auf Initiative des Arztes/der Ärztin.
https://www.bag.admin.ch › richtlinien-empfehlungen › bu-21-15-pict-hiv.
61 Gesellschaft Anthroposophischer Ärzte in Deutschland e.V. und Medizinische Sektion der Freien Hochschule für Geisteswissenschaft, Dornach, Schweiz, Vademecum Anthroposophische Arzneimittel, Merkurstab. 2017(4).
62 Soldner, G. and H.M. Stellmann. Individuelle Pädiatrie. Stuttgart, Wissenschaftliche Verlagsgesellschaft. 2018(5): p. 264.
63 Dickens, K.P., et al. Clinical inquiries. Should you use steroids to treat infectious mononucleosis? J Fam Pract. 2008;57(11):754–5.
64 Patel, B.M. Skin rash with infectious mononucleosis and ampicillin. Pediatrics. 1967;40(5):910–1.
65 Patel, B.M. Morbilliform rashes appearing in the terminal phase of the epidemic viral respiratory illnesses in December 1967 and January 1968. Pediatrics. 1968;42(1):209.
66 Pullen, H., N. Wright, and J.M. Murdoch. Hypersensitivity reactions to antibacterial drugs in infectious mononucleosis. Lancet. 1967;2(7527):1176–8.
67 Chovel-Sella, A., et al. Incidence of Rash After Amoxicillin Treatment in Children With Infectious Mononucleosis. Pediatrics. 2013;131(5):e1424–e1427.
68 Hocqueloux, L., et al. Do penicillins really increase the frequency of a rash when given during Epstein-Barr Virus primary infection? Clin Infect Dis. 2013;57(11):1661–2.
69 Burroughs, K.E. Athletes resuming activity after infectious mononucleosis. Arch Fam Med. 2000;9(10):1122–3.
70 Bartlett, A., R. Williams, and M. Hilton. Splenic rupture in infectious mononucleosis: A systematic review of published case reports. Injury. 2016;47(3):531–8.
71 Waninger, K.N. and H.T. Harcke. Determination of safe return to play for athletes recovering from infectious mononucleosis: a review of the literature. Clin J Sport Med. 2005;15(6):410–6.
72 Shephard, R.J. Exercise and the Athlete With Infectious Mononucleosis. Clin J Sport Med. 2017;27(2):168–78.
73 Lennon, P., et al. Challenging the use of the lymphocyte to white cell count ratio in the diagnosis of infectious mononucleosis by analysis of a large cohort of Monospot test results. Clinical Otolaryngology. 2010;35(5):397–401.
74 Thorley-Lawson, D.A. and A. Gross. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. N Engl J Med. 2004;350(13):1328–37.
75 Centers for Disease Control and Prevention. Epstein-Barr Virus and Infectious Mononucleosis [Internet]. 2018; Available from: https://www.cdc.gov/epstein-barr/about-ebv.html.
76 Kimura, H., et al. Clinical and virologic characteristics of chronic active Epstein-Barr virus infection. Blood. 2001;98(2):280–6.
77 Cohen, J.I., et al. Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood. 2011;117(22):5835–49.
78 Kawamoto, K., et al. A distinct subtype of Epstein-Barr virus-positive T/NK-cell lymphoproliferative disorder: adult patients with chronic active Epstein-Barr virus infection-like features. haematologica. 2018;103(6):1018–28.
79 Macsween, K.F., et al. Infectious mononucleosis in university students in the United kingdom: evaluation of the clinical features and consequences of the disease. Clin Infect Dis. 2010;50(5):699–706.
80 Buchwald, D.S., et al. Acute infectious mononucleosis: characteristics of patients who report failure to recover. Am J Med. 2000;109(7):531–7.
81 White, P.D., et al. Predictions and associations of fatigue syndromes and mood disorders that occur after infectious mononucleosis. The Lancet. 2001;358(9297):1946–54.
82 Hickie I., et al. Post-infective and chronic fatigue syndromes precipitated by viral and non-viral pathogens: prospective cohort study. BMJ. 2006;333(7568):575.
83 Cope H, et al. Predictors of chronic “postviral” fatigue. The Lancet. 1994;344(8926):864–8.
84 Candy B, et al. Predictors of fatigue following the onset of infectious mononucleosis. Psychological medicine. 2003;33(5):847–55.
85 Katz BZ, et al. Chronic fatigue syndrome after infectious mononucleosis in adolescents. Pediatrics. 2009;124(1):189–93.
86 Clark MR, et al. Chronic fatigue: risk factors for symptom persistence in a 2 1/2-year follow-up study. The American Journal of Medicine. 1995;98(2):187–95.
87 Petersen I, et al. Risk and predictors of fatigue after infectious mononucleosis in a large primary-care cohort. Qjm. 2006;99(1):49–55.
88 Katz BZ, et al. The international collaborative on fatigue following infection (COFFI). Fatigue: biomedicine, health & behavior, 2018;6(2):106–21.
89 Candy B, et al. Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review. Br J Gen Pract. 2002;52(483):844–51.
90 Asprusten TT, et al. EBV-requisitioning physicians’ guess on fatigue state 6 months after acute EBV infection. BMJ paediatrics open. 2019;3(1): p. e000390.
91 Cameron B, et al. Prolonged illness after infectious mononucleosis is associated with altered immunity but not with increased viral load. J Infect Dis. 2006;193(5):664–71.
92 Pedersen M, et al. Fatigue in Epstein-Barr virus infected adolescents and healthy controls: A prospective multifactorial association study. Journal of psychosomatic research, 2019;121:46–59.
93 Cameron B, et al. Serum cytokine levels in postinfective fatigue syndrome. Clin Infect Dis. 2010;50(2):278–9.
94 Galbraith S, et al. Peripheral blood gene expression in postinfective fatigue syndrome following from three different triggering infections. Journal of Infectious Diseases. 2011;204(10):1632–40.
95 Welch M.J. and L. Wheeler. Aerobic capacity after contracting infectious mononucleosis. Journal of Orthopaedic Sports Physical Therapy. 1986;8(4):199–202.
96 Allen, C., P. Glasziou, and C. Del Mar. Bed rest: a potentially harmful treatment needing more careful evaluation. The Lancet. 1999;354(9186):1229–33.
97 Repsher, L.H. and R.K. Freebern. Effects of early and vigorous exercise on recovery from infectious hepatitis. N Engl J Med. 1969;281(25):1393–6.
98 Auwaerter, P.G. Infectious mononucleosis in active patients: definitive answers to common questions. The Physician and sportsmedicine. 2002;30(11):43–50.
99 Clauw D.J. Guided graded exercise self-help as a treatment of fatigue in chronic fatigue syndrome. The Lancet. 2017;390(10092):335–6.
100 Clark L.V., et al. Guided graded exercise self-help plus specialist medical care versus specialist medical care alone for chronic fatigue syndrome (GETSET): a pragmatic randomised controlled trial. The Lancet. 2017;390(10092):363–73.
101 Chalder T., et al. Rehabilitative therapies for chronic fatigue syndrome: a secondary mediation analysis of the PACE trial. The Lancet Psychiatry. 2015;2(2):141–52.
102 Larun L., et al. Exercise therapy for chronic fatigue syndrome. Cochrane database of systematic reviews, 2017. 4: p. Cd003200.
103 Marques, M.M., et al. Differential effects of behavioral interventions with a graded physical activity component in patients suffering from Chronic Fatigue (Syndrome): An updated systematic review and meta-analysis. Clinical psychology review. 2015;40:123–37.
104 White, P.D., et al., Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. The Lancet. 2011;377(9768):823–36.
105 Bleijenberg, G. and H. Knoop. Chronic fatigue syndrome: where to PACE from here? The Lancet. 2011;377(9768):786–8.
106 Salit, I.E. Precipitating factors for the chronic fatigue syndrome. Journal of psychiatric research. 1997;31(1):59–65.
107 Katon, W., et al. Infectious mononucleosis: psychological symptoms during acute and subacute phases of illness. Gen Hosp Psychiatry. 1999;21(1):21–9.
108 Majid A., et al. Epstein-Barr virus myeloradiculitis and encephalomyeloradiculitis. Brain. 2002;125(Pt 1):159–65.
109 Gilden D.H., et al. Herpesvirus infections of the nervous system. Nat Clin Pract Neurol. 2007;3(2):82–94.
110 Corssmit E.P., et al. Severe neurological complications in association with Epstein-Barr virus infection. J Neurovirol. 1997;3(6):460–4.
111 Phowthongkum P., et al. Basal ganglia and brainstem encephalitis, optic neuritis, and radiculomyelitis in Epstein-Barr virus infection. J Infect. 2007;54(3):e141–4.
112 Gotoh K., et al. Clinical and virological characteristics of 15 patients with chronic active Epstein-Barr virus infection treated with hematopoietic stem cell transplantation. Clin Infect Dis. 2008;46(10):1525–34.
113 Weinberg, A., et al. Dual infections of the central nervous system with Epstein-Barr virus. J Infect Dis. 2005;191(2):234–7.
114 Jenson, H.B. Acute complications of Epstein-Barr virus infectious mononucleosis. Curr Opin Pediatr. 2000;12(3):263–8.
115 Lucas, R.M., et al. Epstein-Barr virus and multiple sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(10):1142–8.
116 Farrell R.A., et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology. 2009;73(1):32–8.
117 Hassani A., et al. Epstein-Barr virus is present in the brain of most cases of multiple sclerosis and may engage more than just B cells. PloS one. 2018;13(2):e0192109.
118 Roschewski, M. and W.H. Wilson. EBV-associated lymphomas in adults. Best Pract Res Clin Haematol. 2012;25(1):75–89.
119 Hjalgrim H, et al. Characteristics of Hodgkin’s lymphoma after infectious mononucleosis. N Engl J Med. 2003;349(14):1324–32.
120 Hjalgrim H., et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer research. 2007;67(5):2382–8.
1 Lennon P, Crotty M, Fenton JE. Infectious mononucleosis. BMJ. 2015;350:h1825.
2 Ebell MH. Epstein-Barr virus infectious mononucleosis. Am Fam Physician. 2004;70(7):1279–87.
3 Womack J, Jimenez M. Common questions about infectious mononucleosis. Am Fam Physician. 2015;91(6):372–6.
4 Dunmire SK, Hogquist KA, Balfour HH. Infectious Mononucleosis. Curr Top Microbiol Immunol. 2015;390(Pt 1):211–40.
6 Fugl A, Andersen CL. Epstein-Barr virus and its association with disease-a review of relevance to general practice. BMC family practice. 2019;20(1):62.